A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Hypochondroplasia Clinical Trial

Official title:
A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Status Recruiting

Clinical Trial Summary

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

n/a

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05328050` - Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Completed	`NCT01111019` - Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children	Phase 2
Recruiting	`NCT06410976` - Prospective Clinical Assessment Study in Children With Hypochondroplasia
Enrolling by invitation	`NCT06455059` - Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia	Phase 3
Completed	`NCT01541306` - C-Type Natriuretic Peptide and Achondroplasia	N/A